A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis
Clinical trial NCT03384745 · COMPLETED
Trial details
- NCT number
- NCT03384745
- Sponsor
- Bond Avillion 2 Development LP
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-07-31
- Primary completion
- 2019-06-20
- Enrollment
- 313
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.